News and press releases
2011-09-29 14:03
Florence, Kentucky. September 29, 2011. Immudyne, Inc. (Pink Sheets: IMMD) a leading industry provider of all-natural products for immune system support from yeast beta-glucan, is pleased to announce the retirement of 1,136,842 shares of the Company’s common stock purchased in a recent private transaction. Mark McLaughlin, CEO of Immudyne stated, “The retiring of these shares is part of ongoing efforts to enhance the value of our long-term shareholders’ ownership in Immudyne. With only 24.5 million shares currently outstanding, and virtually no company debt, our capital structure accommodates future growth both organically and through strategic opportunities.”
Read more … Immudyne Retires 1.136 Million Shares - Planning Additional Purchases
2011-09-21 14:01
Florence, Kentucky, September 21, 2011. Immudyne, Inc. (Pink Sheets: IMMD) the world's leading research and production firm specializing in immune system support compounds based on Beta Glucan derived from baker's yeast, announced today that it has appointed Jim Roufs as Director of Product Development. Mr. Roufs brings more than twenty years of industry experience in the dietary supplement field to augment Immudyne's research and production team. He previously led New Product Development for more than seven years for the world's largest dietary supplement brand, where he participated in developing and launching numerous products with multimillion dollar annual revenues. Mr. Roufs activities will be focused on food and beverage applications for Immudyne's premier Beta Glucan product, as well as dietary supplements for immune system support and athlete training aids.
Read more … Immudyne Taps Industry Veteran As Director Of Product Development
2011-03-14 12:34
FLORENCE, Ky., March 14, 2011 (GLOBE NEWSWIRE) -- Immudyne, Inc. (Pink Sheets:IMMD - News), the leading supplier of Yeast Beta Glucan, announced today that the Company expects to be fully reporting by the first week of April, 2011, at which time two years of audited financials will be uploaded to www.otcmarkets.com. As previously disclosed, New York based PKF LLP has been retained to conduct the audit.
Read more … Immudyne Completing Audited Financials
2010-11-17 12:00
MUNICH, Germany, Nov 17, 2010 (GlobeNewswire via COMTEX) -- Immudyne, Inc. (Pink Sheets:IMMD) is pleased to announce that Sven Rohmann, MD, PhD presented clinical data on Immudyne's ultra pure beta glucan produced from yeast through a proprietary patented process, in both orally and topically administered forms.
Read more … Immudyne Shows Clinical Data
2010-11-12 12:00
FLORENCE, Ky., Nov 12, 2010 (GlobeNewswire via COMTEX) -- Immudyne, Inc. (Pink Sheets:IMMD), announced today that Sven Rohmann, M.D., Ph.D., a member of the Company's Scientific Advisory Board, will deliver the Immudyne company presentation at BIO-Europe on November 16, 2010. BIO-Europe is Europe's premier biotechnology conference.
Read more … Immudyne Invited to Present at BIO-Europe
2009-06-23 12:00
The Court of Appeals for the Fourth District of Texas issues an OPINION that upholds the earlier Judgment that ImmuDyne, Inc. (not BioPolymer Engineering d/b/a Biothera) is the owner of the following seven patents: (1) U.S. Patent No. 5,576,015 ("the '015 patent"), (2) U.S. Patent No. 5,702,719 ("the '719 patent"), (3) U.S. Patent No. 5,705,184 ("the '184 patent"), (4) U.S. Patent No. 5,519,009 ("the '009 patent"), (5) U.S. Patent No. 5,397,773 ("the '773 patent"), (6) Europatent No. 0,500,718 B1; and (7) Canadian Patent 2072145C (collectively, "the disputed patents").
Read more … Court of Appeals Upholds Judgment in ImmuDyne's Favor Tuesday June 23, 2009
2008-12-10 13:12
FLORENCE, Ky., Dec. 10, 2008 (GLOBE NEWSWIRE) -- ImmuDyne (Other OTC:IMMD.PK - News), the leading supplier of Yeast Beta Glucan, announced today a new study, submitted by Dr. Alan B. Weitberg, has been published in the Journal of Experimental & Clinical Cancer Research.
Read more … ImmuDyne Announces Publication of New Cancer Study
2008-05-28 13:00
FLORENCE, Ky., May 28, 2008 (PRIME NEWSWIRE) -- ImmuDyne (Other OTC:IMMD.PK - News), the leading supplier of Yeast Beta Glucan, announced today that the United States District Court, District Of Minnesota, dismissed all of Biothera's claims regarding United States Patent Nos. 5,223,491, 5,519,009, 5,397,773, 5,702,719 and 5,705,184.
Read more … Immudyne pleased with Minnesota Court Decision
